JP2009519238A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519238A5
JP2009519238A5 JP2008543436A JP2008543436A JP2009519238A5 JP 2009519238 A5 JP2009519238 A5 JP 2009519238A5 JP 2008543436 A JP2008543436 A JP 2008543436A JP 2008543436 A JP2008543436 A JP 2008543436A JP 2009519238 A5 JP2009519238 A5 JP 2009519238A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
bacterium
bacillus
seq
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008543436A
Other languages
English (en)
Japanese (ja)
Other versions
JP5280854B2 (ja
JP2009519238A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/045755 external-priority patent/WO2007064741A2/en
Publication of JP2009519238A publication Critical patent/JP2009519238A/ja
Publication of JP2009519238A5 publication Critical patent/JP2009519238A5/ja
Application granted granted Critical
Publication of JP5280854B2 publication Critical patent/JP5280854B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008543436A 2005-11-29 2006-11-29 消化器、および免疫‐関連疾患の予防または処置のためのバチルスｐｂ６の使用 Expired - Fee Related JP5280854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74051805P 2005-11-29 2005-11-29
US60/740,518 2005-11-29
PCT/US2006/045755 WO2007064741A2 (en) 2005-11-29 2006-11-29 The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013069311A Division JP2013173750A (ja) 2005-11-29 2013-03-28 消化器、および免疫‐関連疾患の予防または処置のためのバチルスｐｂ６の使用

Publications (3)

Publication Number Publication Date
JP2009519238A JP2009519238A (ja) 2009-05-14
JP2009519238A5 true JP2009519238A5 (enExample) 2010-01-28
JP5280854B2 JP5280854B2 (ja) 2013-09-04

Family

ID=38092773

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008543436A Expired - Fee Related JP5280854B2 (ja) 2005-11-29 2006-11-29 消化器、および免疫‐関連疾患の予防または処置のためのバチルスｐｂ６の使用
JP2013069311A Pending JP2013173750A (ja) 2005-11-29 2013-03-28 消化器、および免疫‐関連疾患の予防または処置のためのバチルスｐｂ６の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013069311A Pending JP2013173750A (ja) 2005-11-29 2013-03-28 消化器、および免疫‐関連疾患の予防または処置のためのバチルスｐｂ６の使用

Country Status (13)

Country Link
US (1) US20080057047A1 (enExample)
EP (1) EP1956914B1 (enExample)
JP (2) JP5280854B2 (enExample)
KR (1) KR101470352B1 (enExample)
CN (1) CN101448398B (enExample)
AU (1) AU2006320613B2 (enExample)
BR (1) BRPI0619364A2 (enExample)
CA (1) CA2631289C (enExample)
IL (1) IL191795A (enExample)
NZ (1) NZ569244A (enExample)
RU (1) RU2412241C2 (enExample)
WO (1) WO2007064741A2 (enExample)
ZA (1) ZA200804646B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
PT1993360T (pt) 2005-12-28 2017-05-25 Vertex Pharma Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
PE20120074A1 (es) * 2008-09-17 2012-02-26 Agraquest Inc Composicion que comprende cepa de bacillus subtilis para alimentar animales
MX348019B (es) * 2008-09-24 2017-05-23 Resilux Incorporacion en materiales de organismos termo-resistentes y/o resistentes a la presión.
EP3330255B1 (en) 2009-03-20 2020-12-09 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US20130004475A1 (en) * 2010-03-12 2013-01-03 Misaki Hatanaka Agent for increasing bifidobacteria and reducing the decrease of bifidobacteria in large intestine
DK2547348T3 (da) 2010-03-17 2015-08-24 Bayer Cropscience Lp Fremgangsmåde til anvendelse af en bacillus subtilis-stamme til profylakse og behandling af mave-tarm-tilstande
WO2012009712A2 (en) 2010-07-16 2012-01-19 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
WO2012044984A1 (en) 2010-09-30 2012-04-05 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
CA2834402A1 (en) * 2010-12-29 2012-07-05 Cangene Corporation Clostridium difficile antigens
IL311180A (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
US9393275B2 (en) 2012-08-01 2016-07-19 Novozymes A/S Probiotic for amelioration of coccidiosis vaccine reaction
RU2534356C2 (ru) * 2012-10-04 2014-11-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Россельхозакадемии (ГНУ ИЭВСиДВ Россельхозакадемии) Способ контроля качества дезинфекции птицеводческих помещений
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
FR3007655B1 (fr) * 2013-06-28 2016-12-23 Lesaffre & Cie Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques
EP2923710A1 (en) * 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora
WO2016011511A1 (en) * 2014-07-25 2016-01-28 The University Of Queensland Bacillus amyloliquefaciens probiotic compositions, methods of production, and methods of use
ES2835731T3 (es) 2014-09-30 2021-06-23 Univ Auburn Uso de pectina o sacáridos relacionados con la pectina para mejorar la eficacia de las cepas de rizobacterias que promueven el crecimiento de las plantas (PGPR) para promover el crecimiento y la salud en las plantas
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
JP6595761B2 (ja) * 2014-12-19 2019-10-23 東亜薬品工業株式会社 バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物
ES2954455T3 (es) 2015-01-23 2023-11-22 Novozymes As Cepas de Bacillus que mejoran la salud y el rendimiento de animales de producción
BR112017015623B1 (pt) 2015-01-23 2022-05-31 Novozymes A/S Ração animal ou aditivo de ração animal ou pré-mistura de ração, método para melhora de um ou mais parâmetros de desempenho de um animal e para alimentação de um animal, e, uso de uma cepa de bacillus
WO2016118850A1 (en) 2015-01-23 2016-07-28 Novozymes A/S Bacillus subtilis subspecies
WO2016194427A1 (ja) * 2015-05-30 2016-12-08 日環科学株式会社 プロバイオティクス、あるいはプレバイオティクス、並びにその製造方法、微生物製剤、健康食品並びに医薬品
US10857190B2 (en) 2015-10-06 2020-12-08 Albert Einstein College Of Medicine Microbial hyperswarmers and uses thereof
JP6759337B2 (ja) * 2015-10-26 2020-09-23 シージェー チェイルジェダン コーポレーション 酵素生産能が優秀である伝統発酵食品由来の新たな菌株及びこれを用いた穀物発酵酵素食品の製造方法
RU2641979C1 (ru) * 2016-10-24 2018-01-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) Способ морфологической оценки влияния различных лекарственных форм железа для энтерального применения на тонкий отдел кишечника у экспериментальных животных
EP3645751A1 (en) * 2017-06-30 2020-05-06 Evonik Operations GmbH Bacillus subtilis
US20190289878A1 (en) * 2018-03-23 2019-09-26 Purina Animal Nutrition Llc Methods of feeding animals feed products containing direct-fed microbials
BR122023002250B1 (pt) * 2018-06-07 2024-01-09 Artugen Therapeutics Ltd Composição para o tratamento de c. difficile
US20220160794A1 (en) * 2019-05-14 2022-05-26 Ormendes Sa Use of bacillus amyloliquefaciens and/or bacillus subtilis for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions, compositions thus obtained, and related method
WO2020257769A1 (en) * 2019-06-21 2020-12-24 The Board Of Trustees Of The University Of Arkansas Bacillus isolate compositions and methods of using and producing the same
GB201911925D0 (en) * 2019-08-20 2019-10-02 Sporegen Ltd Formulations for prevention or reduction of c. difficile infections
WO2021116983A1 (en) * 2019-12-11 2021-06-17 Artugen Therapeutics, Ltd. Edible products comprising bacterial strains and methods of use
US20210283199A1 (en) * 2020-03-13 2021-09-16 Kemin Industries, Inc. Method for controlling clostridium infection in animals
GB202013874D0 (en) * 2020-09-03 2020-10-21 Sporegen Ltd Treatment and prevention of viral infections
US12317906B2 (en) 2020-12-09 2025-06-03 Purina Animal Nutrition Llc Feed compositions and methods for inhibiting focal ulcerative dermatitis
CN113151069B (zh) * 2021-04-01 2022-07-26 安杰利(重庆)生物科技有限公司 一种枯草芽孢杆菌及其在制备抗菌肽、饲料中的应用
KR102546973B1 (ko) * 2021-10-20 2023-06-26 주식회사 리빙진 바실러스 밸레젠시스 Kh2-2 균주를 포함하는 면역증강용 조성물
WO2023220279A1 (en) * 2022-05-12 2023-11-16 Can Technologies, Inc. Compositions and methods for the treatment and prevention of campylobacter infection
CN115725461B (zh) * 2022-11-03 2024-03-19 东北农业大学 一株具有抗幽门螺杆菌作用的解淀粉芽孢杆菌及其应用
FR3158224A1 (fr) * 2024-01-12 2025-07-18 Lesaffre Et Compagnie Effet bénéfique d’une bactérie probiotique Bacillus subtilis dans la lutte contre les infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968493A (en) * 1986-06-30 1990-11-06 American Cyanamid Company Method for controlling chronic respiratory disease, fowl cholera and necrotic enteritis in avian species
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
ZA926834B (en) * 1991-09-09 1993-03-15 American Cyanamid Co Antibiotic LL-E19020 Gamma.
TW455591B (en) * 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) * 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2879321B2 (ja) * 1996-03-14 1999-04-05 久保田 豊秋 動物用経口組成物
EP0862863B9 (en) * 1997-01-09 2009-08-12 Societe Des Produits Nestle S.A. Cereal product containing probiotics
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
RU2246537C2 (ru) * 2002-11-11 2005-02-20 Закрытое акционерное общество "КУЛ" Штамм бактерий bacillus subtilis, используемый для получения пробиотического препарата, предназначенного для профилактики и лечения желудочно-кишечных заболеваний сельскохозяйственных животных, птицы и рыбы
US7247299B2 (en) * 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
JP4189224B2 (ja) * 2003-01-14 2008-12-03 株式会社カンサイ バチルス属に属する微生物及びそれを用いる防除剤
KR100535912B1 (ko) * 2003-12-17 2005-12-09 주식회사 케이티앤지 신규한 미생물 바실러스 아밀로리쿼페이션스 케이티지비0202 및 이를 이용한 식물병원균의 방제방법
JP2005198518A (ja) * 2004-01-13 2005-07-28 Asahi Business Support Co Ltd 海苔屑分解処理法及び微生物
RU2270858C2 (ru) * 2004-03-30 2006-02-27 Институт биологии Уфимского научного центра РАН Штамм бактерий b. subtilis - продуцент сурфактина
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders

Similar Documents

Publication Publication Date Title
JP2009519238A5 (enExample)
RU2008121602A (ru) Применение рв6 bacillus для профилактики или лечения желудочно- кишечных и иммунных заболеваний
JP6444358B2 (ja) ペディオコッカスを含有する医薬組成物および消化器症候群の症状を低減する方法
JP2019108378A5 (enExample)
Wullt et al. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial
HRP20191096T1 (hr) Sastavi koje sadrže bakterijske blautia sojeve za liječenje visceralne hipersenzitivnosti
JP2019163267A5 (enExample)
RU2011139211A (ru) Бактериальные штаммы, обладающие высокой противовоспалительной активностью
US20200121740A1 (en) Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
WO2002016554A9 (en) Probiotics products containing lactic acid bacterium
JP2014512376A (ja) 胃酸過多症の薬理学的処置中に失われる胃のバリア効果を回復させることができるプロバイオティック細菌を含む組成物
JP2016529309A5 (enExample)
JP2019508486A5 (enExample)
MX337667B (es) Combinacion simbiotica para mejorar la microbiota intestinal.
RU2010142003A (ru) Синбиотическая смесь
JP2013522315A5 (enExample)
NZ603065A (en) Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
WO2010125421A1 (en) Use of collinsella aerofaciens for reducing bloating
Fayed et al. Co-administration of amoxicillin-loaded chitosan nanoparticles and inulin: A novel strategy for mitigating antibiotic resistance and preserving microbiota balance in Helicobacter pylori treatment
JP2013147469A5 (enExample)
JP2015525566A5 (enExample)
Jin et al. Prebiotic effects of poly-gamma-glutamate on bacterial flora in murine gut
Jiang et al. Protective effects of Bacillus amyloliquefaciens 40 against Clostridium perfringens infection in mice
O'Sullivan Genomics can advance the potential for probiotic cultures to improve liver and overall health
Jang et al. Adhesion activity of Lactobacillus plantarum PM 008 isolated from kimchi on the intestine of mice